Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCheckit Regulatory News (CKT)

Share Price Information for Checkit (CKT)

Share Price is delayed by 15 minutes
Get Live Data
25.00    0.00 (0.00%)
Bid:
24.00
Ask:
26.00
Spread: 2.00 (8.333%)
Market Cap: £27.00m
CKT Live PriceLast checked at - London Stock Exchange

Intraday Checkit Share Chart

Trading Update

28 Jul 2016 07:00

RNS Number : 4408F
Elektron Technology PLC
28 July 2016
 

28 July 2016

 

Elektron Technology plc

(AIM: EKT, "Elektron" or "the Company" or the "Group")

 

Trading Update

 

Ahead of its Annual General Meeting on Thursday 28th July 2016, Elektron Technology plc, the global technology group, provides an update on recent trading.

As already announced at the time of the full year results revenues in the six months ending 31 July 2016 are expected to be lower than those for the same period last year. The Group continues to experience declines in markets for some of its legacy products. Elektron remains committed to its twin strategies of delivering efficiency and productivity improvements in its established businesses and investing in new product development to generate future growth.

Also as previously stated, in the current financial year investment in new product development as well as scale up costs associated with Checkit are expected to absorb much of the cash flow from the established businesses. The Checkit development programme remains on track. The new generation Automated Monitoring module was fully launched towards the end of the first half of the year and a further Checkit solution for SMEs will be launched in the second half.

Group order intake has, until recently, been in line with expectations with the Group's book to bill ratio being 1.04:1 for the current year to date. The Group experienced a drop in orders both immediately before and after the Brexit vote. As a response to the effect on input prices as a result of the drop in sterling, Elektron took action to increase the vast majority of sterling based output prices. In addition the Group is implementing further cost saving initiatives. The Board remains cautious due to the current high level of uncertainty.

Following the previously announced sale of Agar Scientific for initial proceeds of £2.0 million, the Group net cash position is expected to be around £0.3m at 31 July 2016 compared to a net debt position of £1.6m as at 31 January 2016.

The Group expects to announce its results for the half year to 31 July 2016 on 22 September 2016.

 

John Wilson, Chief Executive of Elektron, said:

 

"Despite the current economic uncertainty, the Group continues to make progress in the delivery of new product development programmes in our growth brands, which the Board believes will significantly enhance shareholder value in the medium term."

 

For further information:

 

Elektron Technology www.elektron-technology.com

+44 (0) 1223 371 000

John Wilson - Chief Executive Officer

Andy Weatherstone - Chief Financial Officer

finnCap (Nominated Adviser and Broker)

+44 (0)20 7220 0500

Ed Frisby/Scott Mathieson (Corporate Finance)

Malar Velaigam (Corporate Broking)

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

Notes to Editors

 

Elektron conceives, designs and markets innovative engineered products and services for businesses that connect, monitor and control

 

We have a multi skilled team of engineers, software and product line specialists based in Cambridge focused on the opportunities created by global trends in the following areas:

 

-- New waves of "aware" business applications: Checkit

-- Demand for ubiquitous power and data: Bulgin

-- Growth in high precision manufacture: Queensgate

 

In addition, Elektron owns a portfolio of well-established products and brands that provide cash flow as well as customer access and feedback. 

 

Forward looking statements

 

Statements contained in this trading statement are based on the knowledge and information available to the Company's directors at the date it was prepared and therefore the facts stated and views expressed may change after that date. By their nature, the statements concerning the risks and uncertainties facing the Company in this Statement involve uncertainty since future events and circumstances can cause results and developments to differ materially from those anticipated. To the extent that this Statement contains any statement dealing with any time after the date of its preparation such statement is merely predictive and speculative as it relates to events and circumstances which are yet to occur. The Company undertakes no obligation to update these forward looking statements.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTSEUFIWFMSELW
Date   Source Headline
8th Apr 20269:54 amRNSForm 8.5 (EPT/RI)
7th Apr 202611:44 amRNSForm 8.3 - Checkit plc
7th Apr 202610:30 amRNSForm 8.5 (EPT/RI)
1st Apr 202610:37 amRNSForm 8.5 (EPT/RI)
1st Apr 20269:38 amRNSForm 8.3 - Checkit PLC
1st Apr 20267:47 amRNSForm 8 (OPD) - Checkit plc
31st Mar 20262:50 pmEQSForm 8.3 - Checkit PLC
31st Mar 202611:29 amRNSForm 8.3 - Checkit plc
31st Mar 202611:12 amRNSHolding(s) in Company
31st Mar 202610:51 amRNSForm 8.5 (EPT/RI)
30th Mar 20261:58 pmRNSForm 8.3 - Checkit plc
30th Mar 202610:14 amRNSForm 8.5 (EPT/RI)
27th Mar 20263:39 pmRNSForm 8.3 Check it
27th Mar 20262:43 pmRNSForm 8.3 - Checkit PLC
27th Mar 202611:44 amRNSForm 8.3 - Checkit plc
27th Mar 202611:36 amEQSForm 8.3 - Checkit PLC
27th Mar 202610:40 amRNSForm 8.5 (EPT/RI)
27th Mar 202610:32 amRNSCheckit Plc - Form 8.3
26th Mar 202610:26 amRNSForm 8.3 - Checkit PLC
26th Mar 20267:45 amRNSDisclosure Table
26th Mar 20267:00 amRNSCommencement of Formal Sale Process
19th Feb 20267:00 amRNSFY26 Trading Update
21st Jan 202611:34 amRNSHolding(s) in Company
23rd Dec 20257:00 amRNSDirector/PDMR Shareholding
23rd Dec 20257:00 amRNSDirector/PDMR Shareholding
19th Dec 20257:00 amRNSDirector/PDMR Shareholding
19th Dec 20257:00 amRNSDirector/PDMR Shareholding
28th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20257:00 amRNSDirector/PDMR Shareholding
4th Nov 20257:00 amRNSDirector/PDMR Shareholding
30th Oct 20251:00 pmRNSDirector/PDMR Shareholding
28th Oct 20257:00 amRNSDirector/PDMR Shareholding
13th Oct 20252:52 pmRNSGrant of options and PDMR dealing
25th Sep 20257:00 amRNSDirector/PDMR Shareholding
26th Aug 20257:00 amRNSInterim Results
19th Jun 20252:36 pmRNSGrant of Options
5th Jun 20253:11 pmRNSResult of AGM
29th May 20257:00 amRNSPosting of Annual Report and Notice of AGM
22nd May 20257:00 amRNSDirector/PDMR Shareholding
24th Apr 20257:00 amRNSFinal Results
17th Apr 20257:00 amRNSNotice of Results and Investor Presentation
8th Apr 20257:00 amRNSStrategic update
20th Mar 202512:31 pmRNSForm 8.5 (EPT/RI) - Amendment
20th Mar 202510:21 amRNSForm 8.5 (EPT/RI)
19th Mar 202512:02 pmRNSResult of General Meeting
18th Mar 20259:43 amRNSForm 8.5 (EPT/RI)
18th Mar 20259:23 amRNSForm 8.5 (EPT/NON-RI)
17th Mar 202512:01 pmRNSForm 8.5 (EPT/RI)
17th Mar 20258:56 amRNSForm 8.5 (EPT/NON-RI)
14th Mar 202511:57 amRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.